Molecular Subtype
Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002365CMLExplore in graph →
Hematologic102 active trials3 approved drugs320 evidence items
- NCIt
- C3174
- OncoTree
- CMLBCRABL1
- DOID
- 0081088
- DOID
- 8552
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00002365CMLExplore in graph →
Clinical trials
649 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (104)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03241199 | The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia | unknown | Phase 2 | 15 | The University of Hong KongOTHER | 1 | Aug 8, 2017 | clinicaltrials |
| NCT02975115 | Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization | unknown | — | 102 | Seoul St. Mary's HospitalOTHER | 0 | Nov 29, 2016 | clinicaltrials |
| NCT02949570 | Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study(ICT10) | unknown | Phase 2 | 54 | Hybrigenics CorporationINDUSTRY | 1 | Oct 31, 2016 | clinicaltrials |
| NCT02883036 | Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia | unknown | — | 100 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT02422719 | Radotinib as 3rd or Later Line Therapy in CP-CML(REVITAL) | unknown | Phase 2 | 73 | Ulsan University HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT01802450 | Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase(DASAPOST) | unknown | Phase 2 | 18 | PETHEMA FoundationOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT02389920 | Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib | unknown | Phase 4 | 40 | Samsung Medical CenterOTHER | 0 | Mar 17, 2015 | clinicaltrials |
| NCT02317159 | Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia | unknown | Phase 4 | 90 | CttqINDUSTRY | 0 | Dec 15, 2014 | clinicaltrials |
| NCT02007811 | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination(B-cell therapy) | unknown | Phase 1 / Phase 2 | 15 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 26, 2014 | clinicaltrials |
| NCT01400074 | Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib(RE-NICE) | unknown | Phase 3 | 100 | Seoul St. Mary's HospitalOTHER | 1 | Jan 13, 2014 | clinicaltrials |
| NCT01562847 | Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib(AMICAN) | unknown | — | 125 | Seoul St. Mary's HospitalOTHER | 1 | Jan 13, 2014 | clinicaltrials |
| NCT01564836 | Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib | unknown | N/A | 50 | Seoul St. Mary's HospitalOTHER | 1 | Jan 13, 2014 | clinicaltrials |
| NCT01627132 | Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial | unknown | Phase 2 | 50 | Shimousa Hematology Study GroupOTHER | 1 | Jun 25, 2012 | clinicaltrials |
| NCT00445822 | Registration of Children With CML and Treatment With Imatinib(CML-paed II) | unknown | — | 150 | Technische Universität DresdenOTHER | 1 | Feb 29, 2012 | clinicaltrials |
| NCT00966810 | Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion | unknown | Phase 2 / Phase 3 | 40 | Rambam Health Care CampusOTHER | 1 | Aug 27, 2009 | clinicaltrials |
| NCT00598624 | Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)(AlloTreo) | unknown | Phase 2 | 175 | IRCCS San RaffaeleOTHER | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00815568 | Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) | unknown | Phase 2 | 114 | Samsung Medical CenterOTHER | 1 | Dec 30, 2008 | clinicaltrials |
| NCT00146913 | AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year | unknown | Phase 2 | 30 | Hospices Civils de LyonOTHER | 1 | Apr 27, 2007 | clinicaltrials |
| NCT00328237 | Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation | unknown | Phase 2 | 20 | Colorado Blood Cancer InstituteOTHER | 1 | Jun 26, 2006 | clinicaltrials |
| NCT00327262 | Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase | unknown | Phase 3 | 240 | Central European Leukemia Study GroupOTHER | 1 | Jun 20, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Aug 8, 2017source: clinicaltrials